|
W3C
Reset Setting Change font size to lower sizeChange font size to original sizeChange font size to large size
    T
    T
    T
    T
    T
    T

Advanced Search



Download Attachment
:
 8
 Downloads
A role for cholesterol synthesized de novo by human umbilical cord
Item Type: Article
Author: 
A, Loganath and
R., Gunasegaram and
K.L., Peh and
P.C.T., Chew and
S.S., Ratnam and
Author: 
Editor: 
Year:  00/12/1990
Abstract:  We have previously shown that the human umbilical cord in-vitro possess the ability to synthesize isocaproic acid and presumbly pregnenolone from cholesterol. Here, we examined the ability of the cord to synthesize cholesterol from acetate. Homogenates of umbilical cord (36-41 weeks gestation)obtained following spontaneous vaginal delivery from uncomplicated pregnancies (age 22-31 years) were incubated with [2-14C] acetate. Using the reverse-isotope dilution procedure, cholesterol was isolated and characterized as [14C] cholesterol acetate. Confirmation of identity of newly synthesized cholesterol was obtained after recrystallisation with added non-radioactive cholesterol acetate as standard. The rate of 14C incorporation is small but definite. The results indicate that the homogenates of human term umbilical cord contain the enzymes responsible for the conversion of [2-14C] acetate to [14C] cholesterol. It is suggested that cholesterol synthesized de novo can serve as a percursor for progesterone synthesis in-vivo.
 
 
:
 8
 All Downloads


Download Attachment
:
 11
 Downloads
Coagulation profile in women on low-dose oral contraceptive pills
Item Type: Article
Author: 
Ishak, Roshidah and
Hassan, Khalid and
Yusof, Baharum and
Author: 
Editor: 
Year:  00/12/1990
Abstract:  A cross-sectional study looking at the coagulation system was carried out involving 175 women attending the National Population and Family Development Board's Clinic at the Maternity Clinic, General Hospital, Kuala Lumpur. Study subjects comprise of 50 combined low-dose estrogen/progesterone oral contraceptive (OC) pill users and 75 non-OC users, acting as controls. The subjects were on the pill for a period of one year or more. There were significant shortening of the prothrombin time (PT) and partial thromboplastin time (PTT) in the OC group as compared to the control group. However, the activities of factors II, V and VII assayed were not significantly different between the two groups, suggesting that the changes in the PT and PTT were not significant clinically. The effect of long term usage of combined low-dose OC pills does not seem to indicate changes in the coagulation profile of the women in our study.
 
 
:
 11
 All Downloads


Download Attachment
:
 14
 Downloads
Clinical evaluation of Buserelin, a GnRH analogue in the management of moderate to severe pelvic endometriosis
Item Type: Article
Author: 
M.T.M., Ismail and
H.A., Wadood and
M., Azhar and
Arshat, Hamid and
Author: 
Editor: 
Year:  00/12/1990
Abstract:  A local study, a part of a multinasional and multicenter study on the efficacy and safety of Buserelin was carried out for the treatment of pelvic endometriosis using a standard protocol. 20 women diagnosed to have moderate to severe endometriosis by laparoscopy were recruited. The women were given 900 micrograms Buserelin acetate daily by intranasal spray for a fixed period of 6 months. Baseline hormonal and biochemical parameters were taken prior to treatment and the parameters were repeated during each follow-up at weekly and monthly intervals. In addition, changes in symptoms were monitored. A second look laparoscopy was performed at completion of therapy and patients were followed up for a further 6 months. There was 100 percent suppression of oestradiol levels during the 6 months treatment period. An improvement of implants according to AFS classification occured in all patients. One patient discontinued because of side effects. Restoration of cycles after completion of therapy occured within 7 weeks. There were 7 pregnancies (64%) in the first 6 months after treatment for those wanting pregnancies. During therapy, dysmenorrhoea, pelvic pain and dyspareunia improved considerably. Buserelin was proven to be effective in the management of pelvic endometriosis and is well tolerated and safe.
 
 
:
 14
 All Downloads